| ||||||||||||||||||||||
| ||||||||||||||||||||||
Entries tagged "Genentech"Ray of light for life sciences VCs?The health sector passed a curious milestone: For the first time venture funding of life sciences topped information technology investments. Rising like it's 1987 all over againBloomberg says Thursday's gain extends the market's best monthly gain since 1987. Is Eli Lilly the next pharma to be swallowed?As consolidation in the pharma business continues, Eli Lilly could find itself becoming a target. Advisers in $46.8B Roche-Genentech dealRoche Holdings will finally acquire the remaining 44% of Genentech's shares it doesn't own for $46.8 billion. Deal Stocks: Is M&A Monday back?Despite the return of M&A Monday, the markets failed to rally -- not even merger adviser Morgan Stanley's stock benefited from the news. Roche's Henziker says Genentech acquisition is on trackRoche Holding AG's CFO Erich Hunziker said at the J.P. Morgan Chase & Co. conference that everything is right on track with the Genentech Inc. acquisition. And what about the delay of six months? ... No Avastin bump for GenentechSwiss drug giant Roche Holding AG said Tuesday it's still committed to a "negotiated settlement" in its pursuit of Genentech Inc. The remark came from CEO Severin Schwan during the firm's quarterly earnings call. In July Roche bid $43.7 billion, or $89 a share, for the 44% it doesn't already own. Genentech's board said it was too low but left the door open to higher offers. ... Genentech stays mum on Roche bidGenentech Inc. reported third-quarter earnings late Tuesday. Thanks to its cancer drugs, the news was generally good for the biotech giant. But conference call participants interested in deal news weren't satisfied because Genentech management refused to comment on the progress of the proposed takeover by Roche AG, Genentech's majority owner, which has moved to buy out the 44% it doesn't own for $89 a share. ... The Deal newsweekly, week of Sept. 1Maybe this is the last issue of the summer, or the first issue of the fall. Whatever it is, our preoccupations remain pretty much the same: The financial crisis hangs in there like a particularly ugly summer cold. ... Roche proposes $43.7B Genentech buyoutSwiss drugmaker Roche Holding AG on Monday announced a $43.7 billion offer for the outstanding shares in biotech Genentech Inc. to assist its hunt for new medicines. ... Peter Coors loses another electionThe heir to the Coors brewing empire, Peter Coors, has lost another election. Of course, losing his seat on the board of H.J. Heinz to activist investor Nelson Peltz is not nearly as bad as his 2004 loss for a Colorado U.S. Senate seat, but it still has got to leave a scar on his ego. Nonetheless, Coors will remain the vice chairman of Molson Coors Brewing Co., unless, of course, he loses another election. As for Peltz, he didn't exactly get everything he wanted. Instead of securing five seats on the food company's 12-person board, he only won two.... Top tagsYou have executed a tag search on Dealscape. On the left,you will find a comprehensive list of stories tagged "Genentech." Below are the most-popular tags for Dealscape. On the right of the page you will find a search box to dig deeper into our content.
 Deal Video
    Community
 Elsewhere on The Deal.comDealwatch
The Deal MagazineCorporate Dealmaker
The Deal VideoCategories
Blog roll
Archives
| ||||||||||||||||||||||
| ||||||||||||||||||||||
